ArticleInternational urology and nephrology2026
Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing treatment in PMN: efficacy and safety of rituximab-based regimens.International urology and nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism, vascular inflammation, plaque formation, atherosclerosis, and renal injury. This study aimed to investigate the level of serum PCSK9 and its association with clinical characteristics and particularly major adverse cardiovascular event (MACE) risk in hemodialysis patients.
methodsA Sum of 177 hemodialysis patients and 50 healthy subjects was included in this study. Serum PCSK9 level was determined by enzyme-linked immunosorbent assay. MaCE information is collected in hemodialysis patients with a median follow-up period of 15.8 months.
resultsPCSK9 level was 179.0 [interquartile range (IQR): 106.9-297.7] ng/mL in hemodialysis patients, which was higher than that of 121.0 (IQR: 76.1-185.1) ng/mL in healthy subjects (P < 0.001). PCSK9 level was positively correlated with age (r = 0.202, P = 0.007), total cholesterol (TC) (r = 0.235, P = 0.002), and low-density lipoprotein cholesterol (LDL-C) (r = 0.271, P < 0.001) in hemodialysis patients. 18.1% of hemodialysis patients experienced MACE during the follow-up; PCSK9 level was 287.8 (IQR: 167.3-441.3) ng/mL in cases that experienced MaCE, which was higher than that of 163.3 (IQR: 98.4-277.0) ng/mL in those who did not (P < 0.001). Receiver operator characteristic curve revealed that PCSK9 level could estimate MaCE risk with area under the curve at 0.719, and the best cutoff threshold was 163.5 ng/mL. After adjustment by four models involving different types of parameters, PCSK9 level and PCSK9 > 163.5 ng/mL independently predicted a higher MACE risk.
conclusionSerum PCSK9 level correlates with age, TC, and LDL-C, and predicts a higher MACE risk in hemodialysis patients, indicating its potency as a prognostic biomarker.
Indexed as
Identifiers
41114784What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.